These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37277691)

  • 1. Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance.
    Larcher R; Laffont-Lozes P; Naciri T; Bourgeois PM; Gandon C; Magnan C; Pantel A; Sotto A
    Infection; 2023 Dec; 51(6):1835-1840. PubMed ID: 37277691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report.
    Choi S; Fedorenko M; Lin-Torre J; Mistry N; Smoke S
    Int J Infect Dis; 2022 Sep; 122():1041-1043. PubMed ID: 35932967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
    Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem/vaborbactam activity
    Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
    Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of the Meropenem Component of Meropenem-Vaborbactam in the Treatment of KPC-Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient.
    Hanretty AM; Kaur I; Evangelista AT; Moore WS; Enache A; Chopra A; Cies JJ
    Pharmacotherapy; 2018 Dec; 38(12):e87-e91. PubMed ID: 30300440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia.
    Gatti M; Rinaldi M; Gaibani P; Siniscalchi A; Tonetti T; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Nov; 62(5):106992. PubMed ID: 37778429
    [No Abstract]   [Full Text] [Related]  

  • 12. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
    Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
    Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy.
    Arcari G; Cecilia F; Oliva A; Polani R; Raponi G; Sacco F; De Francesco A; Pugliese F; Carattoli A
    Emerg Infect Dis; 2023 Nov; 29(11):2266-2274. PubMed ID: 37877547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant
    Mouktaroudi M; Kotsaki A; Giamarellos-Bourboulis EJ
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):809-818. PubMed ID: 35034551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report.
    Arcari G; Oliva A; Sacco F; Di Lella FM; Raponi G; Tomolillo D; Curtolo A; Venditti M; Carattoli A
    Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):495-500. PubMed ID: 34988712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem.
    Wang ZQ; Guo ZL; Feng H; Fu C; Zhao GY; Ma K; Zhu L; Chen G
    Curr Med Sci; 2021 Aug; 41(4):770-776. PubMed ID: 34403102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.